COVID-19

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering…

1 year ago

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company…

1 year ago

IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference

New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May…

1 year ago

Entourage Health Reports First Quarter 2023 Financial Results

Total revenue of $15.1 million in Q1 2023 represents a 24% sequential increase over Q4 2022.Net Revenue in medical accounted…

1 year ago

Le Bal Rouge Gala raises $1.68M for MUHC Foundation Dream Big: Breathe Easier Campaign

With the Glitz and Glamour of a 20s Speakeasy, the Gala Honoured the Achievements of Dr. Kevin Schwartzman and the…

1 year ago

BioSenic provides update regarding current license agreement with Phebra

INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024…

1 year ago

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an…

1 year ago

electroCore, Inc. Announces Departure of JP Errico from the Board of Directors

ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced…

1 year ago

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…

1 year ago

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…

1 year ago